1. Home
  2. SGP vs FLGT Comparison

SGP vs FLGT Comparison

Compare SGP & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$26.68

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$14.65

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGP
FLGT
Founded
2019
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
932.9M
867.4M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SGP
FLGT
Price
$26.68
$14.65
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$47.00
$28.33
AVG Volume (30 Days)
82.4K
486.9K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,730,000.00
Revenue This Year
N/A
$10.66
Revenue Next Year
N/A
$12.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.71
$13.46
52 Week High
$30.56
$31.04

Technical Indicators

Market Signals
Indicator
SGP
FLGT
Relative Strength Index (RSI) 53.08 20.89
Support Level $25.50 N/A
Resistance Level $30.02 $19.96
Average True Range (ATR) 1.60 0.99
MACD -0.30 -0.83
Stochastic Oscillator 29.00 9.87

Price Performance

Historical Comparison
SGP
FLGT

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Share on Social Networks: